Incyte to announce full results from Phase 3 tafasitamab study at ASCO

Incyte (INCY) announced that full results from the Phase 3 pivotal study evaluating tafasitamab in first-line diffuse large b-cell lymphoma will be featured as an oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.”